Royal Bank of Canada’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4K | Buy |
855
+375
| +78% | +$2.1K | ﹤0.01% | 6495 |
|
|
2025
Q4 | $3K | Sell |
480
-261
| -35% | -$1.55K | ﹤0.01% | 6829 |
|
|
2025
Q3 | $3K | Buy |
741
+725
| +4,531% | +$3.44K | ﹤0.01% | 6801 |
|
|
2025
Q2 | $0 | Sell |
16
-202
| -93% | -$844 | ﹤0.01% | 7146 |
|
|
2025
Q1 | $1K | Sell |
218
-184
| -46% | -$2.36K | ﹤0.01% | 6667 |
|
|
2024
Q4 | $8K | Sell |
402
-176
| -30% | -$4.04K | ﹤0.01% | 6404 |
|
|
2024
Q3 | $16K | Sell |
578
-59
| -9% | -$1.74K | ﹤0.01% | 6172 |
|
|
2024
Q2 | $18K | Buy |
637
+493
| +342% | +$17.3K | ﹤0.01% | 6111 |
|
|
2024
Q1 | $6K | Sell |
144
-1,185
| -89% | -$53.3K | ﹤0.01% | 6379 |
|
|
2023
Q4 | $71K | Buy |
1,329
+690
| +108% | +$31.1K | ﹤0.01% | 5815 |
|
|
2023
Q3 | $28K | Buy |
639
+194
| +44% | +$8.95K | ﹤0.01% | 6057 |
|
|
2023
Q2 | $24K | Buy |
445
+444
| +44,400% | +$24.4K | ﹤0.01% | 6117 |
|
|
2023
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7232 |
|
|
2022
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 7419 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 7602 |
|
|
2022
Q2 | $0 | Sell |
1
-240
| -100% | -$10.8K | ﹤0.01% | 7501 |
|
|
2022
Q1 | $15K | Sell |
241
-565
| -70% | -$33.4K | ﹤0.01% | 6757 |
|
|
2021
Q4 | $56K | Buy |
806
+361
| +81% | +$25.7K | ﹤0.01% | 6310 |
|
|
2021
Q3 | $31K | Buy |
445
+143
| +47% | +$11.4K | ﹤0.01% | 6441 |
|
|
2021
Q2 | $25K | Buy |
302
+7
| +2% | +$495 | ﹤0.01% | 6447 |
|
|
2021
Q1 | $16K | Sell |
295
-158
| -35% | -$7.69K | ﹤0.01% | 6559 |
|
|
2020
Q4 | $19K | Buy |
453
+353
| +353% | +$13.2K | ﹤0.01% | 6086 |
|
|
2020
Q3 | $3K | Sell |
100
-4
| -4% | -$135 | ﹤0.01% | 6240 |
|
|
2020
Q2 | $3K | Hold |
104
| – | – | ﹤0.01% | 6181 |
|
|
2020
Q1 | $2K | Buy |
104
+2
| +2% | +$54 | ﹤0.01% | 6293 |
|
|
2019
Q4 | $3K | Hold |
102
| – | – | ﹤0.01% | 6484 |
|
|
2019
Q3 | $3K | Hold |
102
| – | – | ﹤0.01% | 6192 |
|
|
2019
Q2 | $2K | Sell |
102
-565
| -85% | -$16.6K | ﹤0.01% | 6571 |
|
|
2019
Q1 | $29K | Buy |
667
+500
| +299% | +$18.1K | ﹤0.01% | 5459 |
|
|
2018
Q4 | $5K | Sell |
167
-55
| -25% | -$2.17K | ﹤0.01% | 6152 |
|
|
2018
Q3 | $12K | Buy |
222
+120
| +118% | +$6.74K | ﹤0.01% | 5905 |
|
|
2018
Q2 | $5K | Sell |
102
-107
| -51% | -$5.48K | ﹤0.01% | 6033 |
|
|
2018
Q1 | $10K | Hold |
209
| – | – | ﹤0.01% | 5712 |
|
|
2017
Q4 | $7K | Buy |
+209
| New | +$7.06K | ﹤0.01% | 5977 |
|
|
2017
Q2 | – | Sell |
-4
| Closed | – | – | 6638 |
|
|
2017
Q1 | $0 | Sell |
4
-2
| -33% | -$58 | ﹤0.01% | 6688 |
|
|
2016
Q4 | $0 | Sell |
6
-994
| -99% | -$25.3K | ﹤0.01% | 6690 |
|
|
2016
Q3 | $27K | Buy |
1,000
+500
| +100% | +$13.9K | ﹤0.01% | 5427 |
|
|
2016
Q2 | $14K | Sell |
500
-400
| -44% | -$12.7K | ﹤0.01% | 5629 |
|
|
2016
Q1 | $27K | Sell |
900
-315
| -26% | -$8.93K | ﹤0.01% | 5376 |
|
|
2015
Q4 | $42K | Sell |
1,215
-138
| -10% | -$4.72K | ﹤0.01% | 5395 |
|
|
2015
Q3 | $51K | Sell |
1,353
-54
| -4% | -$2.51K | ﹤0.01% | 5120 |
|
|
2015
Q2 | $80K | Buy |
1,407
+207
| +17% | +$11.8K | ﹤0.01% | 4951 |
|
|
2015
Q1 | $70K | Hold |
1,200
| – | – | ﹤0.01% | 4803 |
|
|
2014
Q4 | $68K | Hold |
1,200
| – | – | ﹤0.01% | 4912 |
|
|
2014
Q3 | $49K | Hold |
1,200
| – | – | ﹤0.01% | 4956 |
|
|
2014
Q2 | $55K | Hold |
1,200
| – | – | ﹤0.01% | 4794 |
|
|
2014
Q1 | $57K | Buy |
1,200
+600
| +100% | +$27.3K | ﹤0.01% | 4798 |
|
|
2013
Q4 | $28K | Buy |
600
+569
| +1,835% | +$24.9K | ﹤0.01% | 5126 |
|
|
2013
Q3 | $1K | Buy |
+31
| New | +$1.22K | ﹤0.01% | 5958 |
|
Other funds holding HBIO
WCM
VCM
CCM
MIM
NCNMGF
Royal Bank of Canada's HBIO Position: Q1 2026 in Review
Royal Bank of Canada increased its Harvard Bioscience (HBIO) stake by 78% in Q1 2026, buying an estimated $2.1K and bringing the position to 855 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #6495.
Royal Bank of Canada first reported a position in HBIO in Q3 2013 and has held it in 49 quarters since. The position peaked at $80K in Q2 2015. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.
- Royal Bank of Canada held 855 shares of Harvard Bioscience worth $4K as of Q1 2026.
- Royal Bank of Canada bought 375 Harvard Bioscience shares in Q1 2026, an estimated $2.1K.
- Harvard Bioscience made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6495 holding.
- Royal Bank of Canada first reported a position in Harvard Bioscience in Q3 2013 and has held it in 49 quarters since.
- Royal Bank of Canada's Harvard Bioscience position peaked at $80K in Q2 2015.
- 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.